Clinical Trials Browser

Cytokine Release Syndrome, Lymphoma, Neoplasms, Plasma Cell

NCT07166549 2025-12-24

BaseCAR-01

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Phase 1 Active not recruiting

19 enrolled

Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Phase 2 Completed

15 enrolled 17 charts

Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Phase 1/2 Active not recruiting

17 enrolled

LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04975555 2025-09-22

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Phase 2 Active not recruiting

30 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06703216 2025-06-15

PACER

Phase 1/2 Not yet recruiting

24 enrolled

Lymphoid

Cytokine Release Syndrome, Burkitt Lymphoma

NCT06447376 2025-05-11

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Phase 1 Recruiting

20 enrolled

Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin

NCT04466098 2025-01-29

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

Phase 2 Completed

8 enrolled 21 charts

Lymphoid

Cytokine Release Syndrome, COVID-19, Lymphoma, Follicular, Respiratory Distress Syndrome

NCT05510596 2024-08-09

MR-ICANS

Phase NA Completed

25 enrolled

Lymphoid

Cytokine Release Syndrome, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT05414162 2022-06-15

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Unknown

60 enrolled

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Follicular, Multiple Myeloma, Myocarditis

Clinical Trials

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

BaseCAR-01

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

PACER

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

MR-ICANS

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy